Who are Loperamide hydrochloride + simethicone chewable tablet's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loperamide-hydrochloride-simethicone-chewable-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Loperamide hydrochloride + simethicone chewable tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Loperamide hydrochloride + simethicone chewable tablet (Loperamide hydrochloride + simethicone chewable tablet) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiarrheal and antifoaming agent. Area: Gastroenterology.

phase 3 Antidiarrheal and antifoaming agent μ-opioid receptors, gas bubbles Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Loperamide hydrochloride + simethicone chewable tablet (Loperamide hydrochloride + simethicone chewable tablet) — Xian-Janssen Pharmaceutical Ltd.. Loperamide hydrochloride acts on opioid receptors in the gut to slow down intestinal motility, while simethicone reduces surface tension in gas bubbles to facilitate their elimination.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Loperamide hydrochloride + simethicone chewable tablet TARGET	Loperamide hydrochloride + simethicone chewable tablet	Xian-Janssen Pharmaceutical Ltd.	phase 3	Antidiarrheal and antifoaming agent	μ-opioid receptors, gas bubbles

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiarrheal and antifoaming agent class)

Xian-Janssen Pharmaceutical Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Loperamide hydrochloride + simethicone chewable tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/loperamide-hydrochloride-simethicone-chewable-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab